Pulmonary Protection Strategies in Cardiac Surgery: Are We Making Any Progress?

Emad Al Jaaly, 1,2 Mustafa Zakkar, 1 Francesca Fiorentino, 2 and Gianni D. Angelini 1,2

1 Bristol Heart Institute, Bristol Royal Infirmary, Upper Maudlin Street, Bristol BS2 8HW, UK
2 Cardiac Surgery, National Heart and Lung Institute, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 0HS, UK

Received 5 February 2015; Accepted 12 March 2015

Pulmonary dysfunction is a common complication of cardiac surgery. The mechanisms involved in the development of pulmonary dysfunction are multifactorial and can be related to the activation of inflammatory and oxidative stress pathways. Clinical manifestation varies from mild atelectasis to severe respiratory failure. Managing pulmonary dysfunction postcardiac surgery is a multistep process that starts before surgery and continues during both the operative and postoperative phases. Different pulmonary protection strategies have evolved over the years; however, the wide acceptance and clinical application of such techniques remain hindered by the poor level of evidence or the sample size of the studies. A better understanding of available modalities and/or combinations can result in the development of customised strategies for the different cohorts of patients with the potential to hence maximise patients’ and institutes’ benefits.

1. Introduction

Pulmonary dysfunction is a common complication of cardiac surgery that can impact patient’s outcomes and health economics. It is recognised that many patients will have altered pulmonary mechanics after surgery which may appear in a wide range of clinical presentations, from mild atelectasis to life threatening acute lung injury (ALI) or adult respiratory distress syndrome (ARDS) [1–3].

Surgical incisions by abolishing the integrity of the chest wall affect respiratory mechanics leading to impaired respiratory effort. Postoperative pain has been shown to be associated with decreased lung function by precluding deep inspirations. Furthermore, patients undergoing surgical procedures associated with opening the pleura will have increased rates of atelectasis, pleural effusions, and postoperative pain especially in the early postoperative period [4–6].

Cardiopulmonary bypass (CPB) can lead to the activation of different inflammatory and coagulation pathways and alters redox balance due to the passage of blood through the circuit (contact activation) and ischaemia and reperfusion injury [7–10].

Vascular endothelial cells (EC) dysfunction during CPB due to changes in blood flow patterns, shear stress, ischaemia, and reperfusion and circulating cytokines will result in the activation of multiple proinflammatory and proapoptosis pathways [11–14] while suppressing its ability to produce vasoprotective mediators [14–17]. EC activation is known to initiate leukocytes adhesion cascade by the expression of members of the selectin family which are responsible for the initial attachment of leukocytes from circulation. Transmigration of leukocyte through EC (crucial step for leukocytes recruitment to tissue) follows leukocytes attachment and is mediated by the upregulation of different adhesion molecules such as platelet endothelial cell adhesion molecule (PECAM-)1, ICAM-1, and very late antigen-4 (VLA-4) [18–21].

CPB is traditionally associated with inadequate lung perfusion as there is no flow to the pulmonary artery during periods of cross clamping and when the heart is not ejecting blood, and thus blood supply is limited to the bronchial arteries [22]. Pulmonary physiology alteration during CPB can result in disturbing the balance in the blood gas barrier due to the alteration of the different force
affecting the parenchyma thus abolishing gas exchange by passive diffusion at the blood-gas barrier level and leading to ventilation/perfusion mismatch and impaired pulmonary compliance [23, 24]. Moreover, ischaemia during CPB is associated with reduced alveolar blood supply resulting in alveolar ischaemia and hypoxic pulmonary vasoconstriction [25]. Pulmonary vascular endothelial cells dysfunction and activated neutrophils sequestration into lungs parenchyma during period of reperfusion can increase lung tissue permeability and elevate vascular resistance and pulmonary surfactant changes leading to alveolar protein accumulation and pulmonary oedema and driving more ROS and cytokines production [26–28]. This will be manifested as abnormal gas exchange, poor lung mechanics, increased pulmonary shunt fraction and reduced functional residual capacity, and carbon monoxide transfer factor [28–30] (Figure 1).

Blood and blood products usage after surgery can be associated with the production of excessive amount of ROS and systemic and pulmonary inflammation. It has been previously shown that the duration of blood storage before transfusion can influence adverse effect associated with transfusion as there are an increased risk of respiratory insufficiency and the need for prolonged ventilation in patients receiving blood stored for longer than two weeks [10, 31–34].

Here we review the most commonly used strategies to minimise pulmonary dysfunction after cardiac surgery.

### 2. Pulmonary Protection Strategies

#### 2.1. Pharmacological Interventions.

The fact that inflammation and oxidative stress play a pivotal role in the development of pulmonary dysfunction resulted in multiple studies aimed toward modulating such events by the administration of vasodilators and antioxidant and anti-inflammatory medications in experimental animal models or patients undergoing cardiac surgery.

Prostacyclins can induce vascular smooth muscle cells relaxation by the release of intracellular adenosine $3',5'$ cyclic monophosphate (cAMP) resulting in pulmonary and systemic vasodilation [35–38]. Moreover, they can have inhibitory effect on platelet aggregation and leukocytes and monocytes activity [39]. The use of inhaled prostacyclins (Epoprostenol or Flolan) has been shown to decrease pulmonary arterial endothelial dysfunction induced by CPB in experimental studies [40–42]. Furthermore, when administered prior to CPB, they can have beneficial effect in the presence of pulmonary hypertension and may result in lower rate of reintubation in high risk postoperative cardiac patients [43, 44].

Phosphodiesterase inhibitors such as pentoxifylline (PTX) which is a known nonselective phosphodiesterase (PDE) inhibitor can result in elevated levels of intracellular cAMP and vasodilatation. Although PTX has been used classically for claudication symptoms in peripheral vascular disease [45], it has been shown to exert anti-inflammatory and antioxidative properties resulting in modulation of ALI [46–48]. More selective PDE inhibitors such as milrinone can be an advantageous therapeutic strategy for cardiac surgical patients with increased pulmonary vascular resistance (PVR) and right ventricular failure when nebulized and inhaled. It can cause selective pulmonary vasodilation and potentiate the vasodilating effects of inhaled prostacyclin [49, 50].

Nitric oxide (NO) is known to play a pivotal role in vascular endothelial cells homeostasis and regulation of oxidative stress and inflammatory responses [51]. Ischaemia and reperfusion injury during surgery is associated with significant loss in NO; thus NO preconditioning has been suggested to reduce perioperative pulmonary dysfunction and its sequels [52–54]. The protective effects may be due to reversal of posts ischemic lung hypoperfusion and reduction of lung neutrophil sequestration. The administration of NO in patients with severe left ventricular dysfunction can lead to pulmonary vasodilatation and may augment left ventricular filling [55–57]. The timing of administration and/or concentration of inhaled NO during ischaemia or reperfusion periods is a very important determinant of its effect as NO is toxic early in reperfusion, due to its interaction with superoxide which may lead to damage of alveolar type 2 cells [58, 59].

A large number of other drugs have been used with various degrees of success. Aprotinin (serine proteases) had been shown to reduce neutrophil elastase, malondialdehyde, and proinflammatory cytokines levels in bronchoalveolar lavage fluids of patients undergoing cardiac surgery [60]. The use of aprotinin can result in improving lung function and reducing reperfusion lung injury [61]. The administration of corticosteroids before CPB may reduce the activation of multiple proinflammatory mediators. The translation of proinflammatory mediator’s changes into clinical outcomes remains controversial and most of the evidence in the literature originates from small RCTs or observational studies with biomarkers as primary end points [62, 63].

#### 2.2. CPB Modification.

Different strategies have been attempted over the years to minimise proinflammatory activation and oxidative stress when using CPB such as coating the circuit with biocompatible material (heparin, poly-2-methoxyethyl acrylate, synthetic protein, and phosphocholine), removal of leukocytes (by adding special filters to the CPB), ultrafiltration, and reduced haemodilution.
Heparin is thought to reduce the inflammatory responses linked to platelets and leukocytes by reducing the release of IL-6, IL-8, E-selectin, lactoferrin, myeloperoxidase, integrin, selectin, and platelet thromboglobulin and decreasing the production of oxygen free radicals [64–66]. It has been suggested that compared with conventional circuits (poly-2-methoxyethyl acrylate, synthetic protein, and phosphor-ylcholine), the heparin-coated circuit may improve lung compliance and pulmonary vascular resistance and thus reduce intrapulmonary shunt although intubation time and ICU stay were not affected [67, 68].

The use of leukocyte filtration mechanisms can modulate proinflammatory cytokines and oxidative stress [69–71]. A clinical study compared the effectiveness of leukocyte filter depletion with a common arterial filter in CABG patients who reported better oxygenation indices and less duration of postoperative mechanical ventilation in the leukocyte depletion filter group [71]. Another study suggested that leukocyte depletion filters preferentially remove activated leukocytes. Improvement in lung function was evident only in the early postoperative phase, but this did not lead to decreasing mortality or better clinical outcomes [72]. The use of ultrafiltration or modified ultrafiltration techniques at the end of surgery may reduce postoperative oedema specifically that of lungs resulting in better oxygenation and improved lung compliance postoperatively. Furthermore, ultrafiltration may reduce proinflammatory mediators from the circulation such as IL-6 and IL-8 but it did not result in significant improvement of clinical outcomes [73]. Similarly, controlled haemodilution to regulate oncotic pressure can reduce priming volumes and result in better haemodynamic parameters such as vascular resistance and higher oxygen delivery and affect hospital stay significantly [74, 75].

Understanding problems associated with pulmonary ischaemia and reperfusion results in attempts to provide continuous pulmonary perfusion during CPB. Experimental animal models of pulmonary perfusion demonstrated reduced inflammatory and apoptosis pathways activation with such strategy [25, 76, 77]. Moreover, pulmonary perfusion was found to have favorable effect on lung compliance, oxygenation, and vascular resistance in patients undergoing CABG [78, 79]. Furthermore, pulmonary artery perfusion during CPB can be effective in reducing postoperative right ventricular dysfunction in high-risk patients undergoing LVAD placement [80]. The translation of such changes into better clinical outcomes remains unclear and may be restricted to selective group of patients as demonstrated by a recent trial in patients with COPD undergoing cardiac surgery using CPB where no significant protective effect on lungs was documented [81].

The deleterious effects of surface contact activation as discussed previously have led to the development of minimised cardiopulmonary bypass circuit (mini-CPB). This is characterised by reduced surface area and thus priming volume and prevention of air-blood contact. The utilisation of mini-CPB has been shown to be associated with attenuated production of proinflammatory cytokines and complement activation and blunted leukocytes activation compared to conventional circuit. Markers of oxidative stress tend to be reduced in patients undergoing surgery using mini-CPB compared to conventional circuit [82, 83]. Additionally, mini-CPB reduces organ damage and results in better postoperative gas exchange and lower lung injury scores [84, 85]. Unfortunately most of the clinical trials investigating the role of mini-CPB have evaluated diverse technologies of varying complexity and degree of miniaturisation, which would be expected to give rise to heterogeneity in findings.

2.3. Surgical Strategies. It has been suggested that eliminating the usual standard of no lung inflation during CPB by maintaining a degree of lung ventilation may be beneficial. The use of continuous positive airway pressure (CPAP) during CPB may result in less shunt and better gas exchange [86]; however, it seems that such effect is dependent on the airway pressure used. Using low frequency ventilation (LFV) along with CPAP during CPB to reduce post-CPB lung injury has been evaluated in an experimental pig model [87]. This study showed that the use of LFV is associated with significantly better pulmonary gas exchange, higher adenine nucleotide, lower LDH levels, and reduced histological damage in lung biopsies as well as lower DNA levels in bronchoalveolar lavage (BAL) compared to the collapsed lungs control group. However, a clinical study in patients undergoing cardiac surgery compared the effect of low volume ventilation to conventional strategy of no ventilation and demonstrated no significant changes in PVRI, PaO(2)/FiO(2) ratio, postoperative length of stay, and postoperative pulmonary complications [88]. Furthermore, a meta-analysis of 814 cases in 16 RCTs looking at three lung protective strategies in patients during CPB including CPAP, low-volume ventilation, and vital capacity manoeuvres during CPB showed that the effects of the designated techniques are probably short lived with a questionable impact on the long term clinical outcome of the treated patients [89].

Off pump coronary artery bypass (OPCAB) surgery seems to provide better lung protection by eliminating ischemia-reperfusion injury through maintaining lung ventilation and avoiding CPB. Many studies consistently reported better early and midterm outcomes in OPCAB when compared with conventional on-pump CABG: fewer respiratory complications, shorter intubation time and ITU stay, reduced incidence of pneumonia, and overall shorter hospital stay [90–92].

2.4. Physiotherapy. Preoperative prophylactic physiotherapy with inspiratory or expiratory muscle training can be used as a preventative measure for lung protection [93, 94]. Postoperative physiotherapy is used prophylactically in patients undergoing cardiac surgery. Different techniques can be utilised during this period to improve ventilation-perfusion inequalities, increase pulmonary compliance, and help reinflate collapsed alveoli.

These techniques include deep breathing exercises, slow maximal inspirations with an inspiratory hold, intermittent deep breathing exercises with and without the use of incentive spirometer, and deep breathing exercises with expiratory resistance [95–98].
2.5. Postoperative Noninvasive Ventilation (NIV). NIV refers to the administration of ventilatory support without using an invasive artificial airway (endotracheal tube or tracheostomy tube). NIV exerts its main effects on the pulmonary and on the cardiovascular systems through the application of a positive end-expiratory pressure (PEEP); with or without a pressure support during inspiration, NIV restores lung volumes by opening atelectatic areas, increases alveolar ventilation, and reduces the work of breathing [99–101]. Furthermore, the prophylactic use of BLPAP after early extubation has been shown to reduce the hospital stay after cardiac surgery [109–111].

Continuous positive airway pressure (CPAP) aims to maintain a level of positive airway pressure in a spontaneously breathing patient. It is functionally similar to positive end-expiratory pressure (PEEP), except that PEEP is an applied pressure against exhalation and CPAP is a pressure applied by a constant flow. The ventilator does not cycle during CPAP; no additional pressure above the level of CPAP is provided, and patients must initiate all of their breaths. To avoid drying of the respiratory mucosa, there has been general agreement that the application of humidified CPAP helps to recruit the lungs by increasing functional residual capacity (FRC), increase the surface area of lung, decrease intrapulmonary shunt, and improve oxygenation [102–104].

Bilevel positive airway pressure (BLPAP) is a continuous positive airway pressure with pressure support breaths. It delivers a preset inspiratory positive airway pressure (IPAP) during inspiration and expiratory positive airway pressure (EPAP). BLPAP can be described as CPAP with a time-cycled or flow-cycled change of the applied pressure level [105]. BLPAP senses patients breathing efforts by monitoring air flow in the patient’s circuit and adjusts its output by assisting inspiration. Therefore, its physiological effects can benefit the patient in both phases of respiration [106–108]. BLPAP application can only be commenced on conscious, cooperative, and hemodynamically stable patients who can breathe spontaneously, have an adequate gag and cough reflex, and are able to remove the mask when required. Several studies have demonstrated beneficial effects of BLPAP in reducing pulmonary complications and overall length of hospital stay after cardiac surgery [109–111]. Furthermore, the prophylactic use of BLPAP after early extubation has been shown to be safe and effective [111, 112]. A better tolerance was noted when BLPAP settings were commenced on low level and gradually adjusted to achieve the therapeutic target. Radiological improvement of atelectasis after cardiac surgery has been achieved on maintaining 8–10 mL/kg of tidal volume with BLPAP [113].

3. Conclusions

Pulmonary dysfunction is one of the most common and serious complications after cardiac surgery and can significantly impact on patient outcomes and health economics. The mechanisms involved in the development of pulmonary dysfunction are multifactorial and are related to the activation of different inflammatory and oxidative stress pathways. Clinical manifestation varies from mild atelectasis to severe respiratory failure. Managing pulmonary dysfunction postcardiac surgery is a multistep process that starts before surgery and continues during both the operative and postoperative phases. Pulmonary protection strategies have evolved over the years with various degrees of success. The main weakness of the majority of studies is often being observational in nature, small sample size, or being concentrated on a single intervention. Managing pulmonary dysfunction needs to be a multistep process involving more than one modality for each step of the surgical pathway. A better understanding of available modalities and/or combinations will result in the development of customised strategies for the different cohorts of patients. This in turn will help reduce pulmonary dysfunction and hence improve early outcome and costs after cardiac surgery.

Conflict of Interests

No conflict of interests is declared by any of the authors.

Acknowledgment

This research was supported by the National Institute for Health Research Biomedical Research Unit in Cardiovascular Disease at the University Hospitals Bristol NHS Foundation Trust and the University of Bristol.

References

[1] R. Ascione, C. T. Lloyd, M. J. Underwood, A. A. Lotto, A. A. Pitsis, and G. D. Angelini, “Economic outcome of off-pump coronary artery bypass surgery: a prospective randomized study,” The Annals of Thoracic Surgery, vol. 68, no. 6, pp. 2237–2242, 1999.

[2] G. E. Hill, “Cardiopulmonary bypass-induced inflammation: is it important?” Journal of Cardiothoracic and Vascular Anesthesia, vol. 12, no. 2, pp. 21–25, 1998.

[3] E. E. Apostolakis, E. N. Koletsis, N. G. Baikoussis, S. N. Siminelakis, and G. S. Papadopoulos, “Strategies to prevent intraoperative lung injury during cardiopulmonary bypass,” Journal of Cardiothoracic Surgery, vol. 5, no. 1, article 1, 2010.

[4] S. Ali-Hassan-Sayegh, S. J. Mirhosseini, V. Vahabzadeh, and N. Ghaffari, “Should the integrity of the pleura during internal mammary artery harvesting be preserved?” Interactive Cardiovascular and Thoracic Surgery, vol. 19, no. 5, pp. 838–847, 2014.

[5] M. Ragnarsdóttir, Á. Kristjánsdóttir, I. Ingvarsdóttir, P. Hannesson, B. Torfason, and L. P. Cahalin, “Short-term changes in pulmonary function and respiratory movements after cardiac surgery via median sternotomy,” Scandinavian Cardiovascular Journal, vol. 38, no. 1, pp. 46–52, 2004.

[6] T. J. Locke, T. L. Griffiths, H. Mould, and G. J. Gibson, “Rib cage mechanics after median sternotomy,” Thorax, vol. 45, no. 6, pp. 465–468, 1990.

[7] C. Baufreton, J.-J. Corbeau, and F. Pinaud, “Inflammatory response and haematological disorders in cardiac surgery: toward a more physiological cardiopulmonary bypass,” Annales Françaises d’Anesthésie et de Réanimation, vol. 25, no. 5, pp. 510–520, 2006.

[8] J. K. Kirklin, S. Westaby, E. H. Blackstone, J. W. Kirklin, D. E. Chenoweth, and A. D. Pacifico, “Complement and the damaging effects of cardiopulmonary bypass,” Journal of Thoracic and Cardiovascular Surgery, vol. 86, no. 6, pp. 845–857, 1983.

[9] M.-S. Suleiman, K. Zacharowski, and G. D. Angelini, “Inflammatory response and cardioprotection during open-heart
surgery: the importance of anaesthetics,” *British Journal of Pharmacology*, vol. 153, no. 1, pp. 21–33, 2008.

[10] M. Zakkar, G. Guida, M. S. Suleiman, and G. D. Angelini, “Cardiopulmonary bypass and oxidative stress,” *Oxidative Medicine and Cellular Longevity*, vol. 2015, Article ID 189863, 8 pages, 2015.

[11] N. Fiotti, C. Giansante, E. Ponte et al., “Atherosclerosis and inflammation. Patterns of cytokine regulation in patients with peripheral arterial disease,” *Atherosclerosis*, vol. 145, no. 1, pp. 51–60, 1999.

[12] B. Tesfamariam and A. F. DeFelice, “Endothelial injury in the initiation and progression of vascular disorders,” *Vascular Pharmacology*, vol. 46, no. 4, pp. 229–237, 2007.

[13] K. van der Heiden, S. Cuhlmann, L. A. Luong, M. Zakkar, and P. C. Evans, “Role of nuclear factor κB in cardiovascular health and disease,” *Clinical Science*, vol. 118, no. 10, pp. 593–605, 2010.

[14] E. M. Boyle Jr., S. T. Lille, E. Allaire, A. W. Clowes, and E. D. Verrier, “Endothelial cell injury in cardiovascular surgery: atherosclerosis,” *The Annals of Thoracic Surgery*, vol. 63, no. 3, pp. 885–894, 1997.

[15] M. Gao, B. Xie, C. Gu, H. Li, F. Zhang, and Y. Yu, “Targeting the proinflammatory cytokine tumor necrosis factor-α to alleviate cardiopulmonary bypass-induced lung injury (review),” *Molecular Medicine Reports*, vol. 11, pp. 2373–2378, 2014.

[16] S. R. Khan, “Reactive oxygen species, inflammation and calcium oxalate nephrolithiasis,” *Translational Andrology and Urology*, vol. 3, pp. 256–267, 2014.

[17] L. Rochette, J. Lorin, M. Zeller et al., “Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets?” *Pharmacology and Therapeutics*, vol. 140, no. 3, pp. 239–257, 2013.

[18] W. A. Muller, “Leukocyte-endothelial-cell interactions in leukocyte transmigration and the inflammatory response,” *Trends in Immunology*, vol. 24, no. 6, pp. 327–334, 2003.

[19] R. P. McEver, “Selectins,” *Current Opinion in Immunology*, vol. 6, no. 1, pp. 75–84, 1994.

[20] R. P. McEver, “Selectins: lectins that initiate cell adhesion under flow,” *Current Opinion in Cell Biology*, vol. 14, no. 5, pp. 581–586, 2002.

[21] M. L. Dustin, R. Rothlein, A. K. Bhan, C. A. Dinarello, and T. A. Springer, “Induction by IL-1 and interferon-γamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1),” *The Journal of Immunology*, vol. 137, pp. 245–254, 1986, The Journal of Immunology (Baltimore, Md, 1950), vol. 186, pp. 5024–5033, 2011.

[22] C. S. H. Ng, S. Wan, A. P. C. Yim, and A. A. Arifi, “Pulmonary dysfunction after cardiac surgery,” *Chest*, vol. 121, no. 4, pp. 1269–1277, 2002.

[23] L. Magnusson, V. Zemgulis, S. Wicky, H. Thydén, S. Thelin, and G. Hedenstierna, “Atelectasis is a major cause of hypoxemia and shunt after cardiopulmonary bypass: An experimental study,” *Anesthesiology*, vol. 87, no. 5, pp. 1153–1163, 1997.

[24] J. Verheij, A. van Lingen, P. G. H. M. Rajmakers et al., “Pulmonary abnormalities after cardiac surgery are better explained by atelectasis than by increased permeability oedema,” *Acta Anaesthesiologica Scandinavica*, vol. 49, no. 9, pp. 1302–1310, 2005.

[25] W. Li, X. Wu, F. Yan et al., “Effects of pulmonary artery perfusion with urinary tryptase inhibitor as a lung protective strategy under hypothermic low-flow cardiopulmonary bypass in an infant piglet model,” *Perfusion*, vol. 29, no. 5, pp. 434–442, 2014.

[26] M. E. Callister, A. Burke-Gaffney, G. J. Quinlan et al., “Extracellular thioredoxin levels are increased in patients with acute lung injury,” *Thorax*, vol. 61, no. 6, pp. 521–527, 2006.

[27] N. J. Lamb, J. M. C. Gutterridge, C. Baker, T. W. Evans, and G. J. Quinlan, “Oxidative damage to proteins of bronchoalveolar lavage fluid in patients with acute respiratory distress syndrome: evidence for neutrophil-mediated hydroxilation, nitration, and chlorination,” *Critical Care Medicine*, vol. 27, no. 9, pp. 1738–1744, 1999.

[28] C. Weissman, “Pulmonary complications after cardiac surgery,” *Seminars in Cardiothoracic and Vascular Anesthesia*, vol. 8, no. 3, pp. 185–211, 2004.

[29] C. Goodyear-Bruch and J. D. Pierce, “Oxidative stress in critically ill patients,” *The American Journal of Critical Care*, vol. 11, no. 6, pp. 543–551, 2002.

[30] M. F. Vidal Melo, G. Musch, and D. W. Kaczka, “Pulmonary pathophysiology and lung mechanics in anesthesiology: a case-based overview,” *Anesthesiology Clinics*, vol. 30, no. 4, pp. 759–784, 2012.

[31] H. Relevy, A. Koskharyev, N. Manny, S. Yedgar, and G. Barshstein, “Blood banking-induced alteration of red blood cell flow properties,” *Transfusion*, vol. 48, no. 1, pp. 136–146, 2008.

[32] K. Karkouti, “Transfusion and risk of acute kidney injury in cardiac surgery,” *British Journal of Anaesthesia*, vol. 109, supplement 1, pp. 129–138, 2012.

[33] M. Bitargil, C. Arslan, H. Başbuğ, H. Göçer, Y. Günerhan, and Y. Bekov, “Transfusion-related acute lung injury following coronary artery bypass graft surgery,” *Perfusion*, 2015.

[34] R. Dasararaju and M. B. Marques, “Adverse effects of transfusion,” *Cancer Control*, vol. 22, pp. 16–25, 2015.

[35] J. Raud, “Vasodilatation and inhibition of mediator release represent two distinct mechanisms for prostaglandin modulation of acute mast cell-dependent inflammation,” *The British Journal of Pharmacology*, vol. 99, no. 3, pp. 449–454, 1990.

[36] Z. Raslan and K. M. Naseem, “Compartmentalisation of AMP-dependent signalling in blood platelets: the role of lipid rafts and actin polymerisation,” *Platelets*, pp. 1–9, 2014.

[37] A. H. Sprague and R. A. Khalil, “Inflammatory cytokines in vascular dysfunction and vascular disease,” *Biochemical Pharmacology*, vol. 78, no. 6, pp. 539–552, 2009.

[38] J.-I. Kawabe, F. Ushikubi, and N. Hasebe, “Prostacyclin in vascular diseases—recent insights and future perspectives,” *Circulation Journal*, vol. 74, no. 5, pp. 836–843, 2010.

[39] G. Kemming, O. Habler, M. Kleen, H. Kisch-Wedel, M. Welte, and B. Zwissler, “Searching the ideal inhaled vasodilator: from nitric oxide to prostacyclin,” *European Surgical Research*, vol. 34, no. 1–2, pp. 196–202, 2002.

[40] M. Häch, A. Denault, S. Béliele et al., “Inhaled epoprostenol (prostacyclin) and pulmonary hypertension before cardiac surgery,” *Journal of Thoracic and Cardiovascular Surgery*, vol. 125, no. 3, pp. 642–649, 2003.

[41] C. J. de Wet, D. G. Afleck, E. Jacobsohn et al., “Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery,” *The Journal of Thoracic and Cardiovascular Surgery*, vol. 127, no. 4, pp. 1058–1067, 2004.

[42] S. Rex, G. Schaelte, S. Metzelder et al., “Inhaled iloprost to control pulmonary artery hypertension in patients undergoing mitral valve surgery: a prospective, randomized-controlled trial,” *Acta Anaesthesiologica Scandinavica*, vol. 52, no. 1, pp. 65–72, 2008.
[43] S. Fortier, R. G. DeMaria, Y. Lamarche et al., "Inhaled prostacyclin reduces cardiopulmonary bypass-induced pulmonary endothelial dysfunction via increased cyclic adenosine monophosphate levels," *Journal of Thoracic and Cardiovascular Surgery*, vol. 128, no. 1, pp. 109–116, 2004.

[44] S. M. Lowson, A. Doctor, B. K. Walsh, and P. A. Doorley, "Inhaled prostacyclin for the treatment of pulmonary hypertension after cardiac surgery," *Critical Care Medicine*, vol. 30, no. 12, pp. 2762–2764, 2002.

[45] J. M. Porter, B. S. Cutler, B. Y. Lee et al., "Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients," *American Journal Heart*, vol. 104, no. 1, pp. 66–72, 1982.

[46] C. Michetti, R. Coimbra, D. B. Hoyt, W. Loomis, W. Junger, and P. Wolf, "Pentoxifylline reduces acute lung injury in chronic endotoxemia," *Journal of Surgical Research*, vol. 115, no. 1, pp. 92–99, 2003.

[47] S. Kreth, C. Ledderose, B. Luchting, F. Weis, and M. Thiel, "Immunomodulatory properties of pentoxifylline are mediated via adenosine-dependent pathways," *Shock*, vol. 34, no. 1, pp. 10–16, 2010.

[48] F. M. Konrad, G. Neudeck, I. Vollmer, K. C. Ngamsri, M. Thiel, and J. Reutershoff, "Protective effects of pentoxifylline in pulmonary inflammation are adenosine receptor A2A dependent," *The FASEB Journal*, vol. 27, no. 9, pp. 3524–3535, 2013.

[49] V. H. Kumar, D. D. Swartz, N. Rashid et al., "Prostacyclin and milrinone by aerosolization improve pulmonary hemodynamics in newborn lambs with experimental pulmonary hypertension," *Journal of Applied Physiology*, vol. 109, no. 3, pp. 677–684, 2010.

[50] Á. Haraldsdóttir, N. Kieler-Jensen, and S.-E. Ricksten, "The additive pulmonary vasodilatory effects of inhaled prostacyclin and inhaled milrinone in postcardiac surgical patients with pulmonary hypertension," *Anesthesia & Analgesia*, vol. 93, no. 6, pp. 1439–1445, 2001.

[51] P. Song and M.-H. Zou, "Redox regulation of endothelial cell fate," *Cellular and Molecular Life Sciences*, vol. 71, no. 17, pp. 3219–3239, 2014.

[52] B. Guery, R. Nievre, N. Viget et al., "Inhaled NO preadministration modulates local and remote ischemia-reperfusion organ injury in a rat model," *Journal of Applied Physiology*, vol. 87, no. 1, pp. 47–53, 1999.

[53] E. A. Bach, H. Sellak, S. Murakami et al., "Inhaled nitric oxide attenuates reperfusion injury in non-heartbeating-donor lung transplantation," *Transplantation*, vol. 63, no. 10, pp. 1380–1386, 1997.

[54] V. Brovkovych, X.-P. Gao, E. Ong et al., "Augmented inducible nitric oxide synthase expression and increased NO production reduce sepsis-induced lung injury and mortality in myeloperoxidase-null mice," *American Journal of Physiology—Lung Cellular and Molecular Physiology*, vol. 295, no. 1, pp. L96–L103, 2008.

[55] K. D. Bloch, F. Ichinose, J. D. Roberts Jr., and W. M. Zapol, "Inhaled NO as a therapeutic agent," *Cardiovascular Research*, vol. 75, no. 2, pp. 339–348, 2007.

[56] L. C. Price, S. J. Wort, S. J. Finney, P. S. Marino, and S. J. Brett, "Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review," *Critical Care*, vol. 14, no. 5, article R169, 2010.

[57] F. Ichinose, J. D. Roberts Jr., and W. M. Zapol, "Inhaled nitric oxide: a selective pulmonary vasodilator: current uses and therapeutic potential," *Circulation*, vol. 109, no. 25, pp. 3106–3111, 2004.

[58] Y. Naka, D. K. Roy, A. J. Smerling et al., "Inhaled nitric oxide fails to confer the pulmonary protection provided by distal stimulation of the nitric oxide pathway at the level of cyclic guanosine monophosphate," *The Journal of Thoracic and Cardiovascular Surgery*, vol. 110, no. 5, pp. 1434–1441, 1995.

[59] M. J. Eppinger, P. A. Ward, M. L. Jones, S. F. Bolling, and G. M. Deeb, "Disparate effects of nitric oxide on lung ischemia-reperfusion injury," *The Annals of Thoracic Surgery*, vol. 60, no. 5, pp. 1169–1176, 1995.

[60] G. E. Hill, R. Pohoreckii, A. Alonso, S. I. Rennard, and R. A. Robbins, "Aprotinin reduces interleukin-8 production and lung neutrophil accumulation after cardiopulmonary bypass," *Anesthesia and Analgesia*, vol. 83, no. 4, pp. 696–700, 1996.

[61] M. Erdogan, S. Kalaycioglu, and E. Iriz, "Protective effect of aprotinin against lung damage in patients undergoing CABG surgery," *Acta Cardiologica*, vol. 60, no. 4, pp. 367–372, 2005.

[62] A. Viviano, R. Kanagasababy, and M. Zakkar, "Is perioperative corticosteroid administration associated with a reduced incidence of postoperative atrial fibrillation in adult cardiac surgery?" *Interactive Cardiovascular and Thoracic Surgery*, vol. 18, no. 2, pp. 225–229, 2014.

[63] M. Zakkar and R. Kanagasababy, "Glucocorticoids in adult cardiac surgery; old drugs revisited," *Perfusion*, vol. 28, no. 5, pp. 395–402, 2013.

[64] P. W. Weerwind, J. G. Maessen, L. J. H. van Tits et al., "Influence of Duraflo II heparin-treated extracorporeal circuits on the systemic inflammatory response in patients having coronary bypass," *The Journal of Thoracic and Cardiovascular Surgery*, vol. 110, no. 6, pp. 1633–1641, 1995.

[65] M. Bozdaj, J. Borowiec, L. Nilsson, P. Venge, S. Thelin, and H. E. Hansson, "Effects of heparin coating of cardiopulmonary bypass circuits on in vitro oxygen free radical production during coronary bypass surgery," *Artificial Organs*, vol. 20, no. 9, pp. 1008–1016, 1996.

[66] M. Fukutomi, S. Kobayashi, K. Niwaya, Y. Hamada, and S. Kitamura, "Changes in platelet, granulocyte, and complement activation during cardiopulmonary bypass using heparin-coated equipment," *Artificial Organs*, vol. 20, no. 7, pp. 767–776, 1996.

[67] S. Wan, J.-L. Leclerc, M. Antoine, J.-M. Desmet, A. P. C. Yim, J.-J. Vincent, "Heparin-coated circuits reduce myocardial injury in heart or heart–lung transplantation: a prospective, randomized study," *The Annals of Thoracic Surgery*, vol. 68, no. 4, pp. 1230–1235, 1999.

[68] M. Ranucci, S. Cirri, D. Conti et al., "Beneficial effects of Duraflo II heparin-coated circuits on postperfusion lung dysfunction," *The Annals of Thoracic Surgery*, vol. 61, no. 1, pp. 76–81, 1996.

[69] K. Bando, R. Pillai, D. E. Cameron et al., "Leukocyte depletion during cardiopulmonary bypass improves free radical-mediated lung injury after cardiopulmonary bypass," *Circulation*, vol. 99, no. 5, pp. 873–877, 1999.

[70] J. H. Lemmer Jr., E. W. Dilling, J. R. Morton et al., "Aprotinin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens," *Annals of Thoracic Surgery*, vol. 62, no. 6, pp. 1659–1668, 1996.

[71] S. V. Sheppard, R. V. Gibbs, and D. C. Smith, "Does leucocyte depletion during cardiopulmonary bypass improve oxygenation indices in patients with mild lung dysfunction?" *British Journal of Anaesthesia*, vol. 93, no. 6, pp. 789–792, 2004.
[72] C. Alexiou, S. Sheppard, A. Tang et al., “Leukocytes-depleting filters preferentially remove activated leukocytes and reduce the expression of surface adhesion molecules during the simulated extracorporeal circulation of human blood,” ASAIO Journal, vol. 52, no. 4, pp. 438–444, 2006.

[73] M. Zakkar, G. Guida, and G. D. Angelini, “Modified ultrafiltration in adult patients undergoing cardiac surgery,” Interactive CardioVascular and Thoracic Surgery, vol. 20, no. 3, pp. 415–421, 2015.

[74] R. H. Habib, A. Zacharias, T. A. Schwann et al., “Role of hemodilutional anemia and transfusion during cardiopulmonary bypass in renal injury after coronary revascularization: implications on operative outcome,” Critical Care Medicine, vol. 33, no. 8, pp. 1749–1756, 2005.

[75] O. M. Theusinger, C. Felix, and D. R. Spahn, “Strategies to reduce the use of blood products: a European perspective,” Current Opinion in Anaesthesiology, vol. 25, no. 1, pp. 59–65, 2012.

[76] X. Yewei, D. Liya, Z. Jinghao, Z. Rufang, and S. Li, “Study of the mechanism of pulmonary protection strategy on pulmonary injury with deep hypothermia low flow,” European Review for Medical and Pharmacological Sciences, vol. 17, no. 7, pp. 879–885, 2013.

[77] M. Siepe, U. Goebel, A. Mecklenburg et al., “Pulsatile pulmonary perfusion during cardiopulmonary bypass reduces the pulmonary inflammatory response,” Annals of Thoracic Surgery, vol. 86, no. 1, pp. 115–122, 2008.

[78] F. Santini, F. Onorati, M. Tellesca et al., “Selective pulmonary pulsatile perfusion with oxygenated blood during cardiopulmonary bypass attenuates lung tissue inflammation but does not affect circulating cytokine levels,” European Journal of Cardio-Thoracic Surgery, vol. 42, no. 6, Article ID eza199, pp. 942–950, 2012.

[79] F. Santini, F. Onorati, M. Tellesca et al., “Pulsatile pulmonary perfusion with oxygenated blood ameliorates pulmonary hemodynamic and respiratory indices in low-risk coronary artery bypass patients,” European Journal of Cardio-Thoracic Surgery, vol. 40, no. 4, pp. 794–803, 2011.

[80] F. I. B. Macedo, A. L. Panos, F. M. Andreopoulos, T. A. Salerno, and S. M. Pham, “Lang perfusion and ventilation during implantation of left ventricular assist device as a strategy to avoid postoperative pulmonary complications and right ventricular failure,” Interactive CardioVascular and Thoracic Surgery, vol. 17, no. 5, pp. 764–766, 2013.

[81] A.-H. Kiessling, F. W. Guo, Y. Gökdemir et al., “The influence of selective pulmonary perfusion on the inflammatory response and clinical outcome of patients with chronic obstructive pulmonary disease undergoing cardiopulmonary bypass,” Interactive CardioVascular and Thoracic Surgery, vol. 18, no. 6, pp. 732–739, 2014.

[82] W. B. Gerritsen, W.-J. P. van Boven, D. S. Boss, F. J. Haas, E. P. van Dongen, and L. P. Aarts, “Malondialdehyde in plasma, a biomarker of global oxidative stress during mini-CABG compared to on- and off-pump CABG surgery; a pilot study,” Interactive CardioVascular and Thoracic Surgery, vol. 5, no. 1, pp. 27–31, 2006.

[83] W.-J. van Boven, W. B. Gerritsen, F. G. Waanders, F. J. Haas, and L. P. Aarts, “Mini extracorporeal circuit for coronary artery bypass grafting: initial clinical and biochemical results: a comparison with conventional and off-pump coronary artery bypass grafts concerning global oxidative stress and alveolar function,” Perfusion, vol. 19, no. 4, pp. 239–246, 2004.

[84] H. A. Vohra, R. Whistance, A. Modi, and S. K. Ohri, “The inflammatory response to miniaturised extracorporeal circulation: a review of the literature,” Mediators of Inflammation, vol. 2009, Article ID 707042, 7 pages, 2009.

[85] J. Zeitani, F. Buccisano, S. Nardella et al., “Mini-extracorporeal circulation minimizes coagulation abnormalities and ameliorates pulmonary outcome in coronary artery bypass grafting surgery,” Perfusion, vol. 28, no. 4, pp. 298–305, 2013.

[86] A. Loeckinger, A. Kleinsasser, K. H. Lindner, J. Margreiter, C. Ripp, and P. Kranke, “The effect of different lung-protective strategies in patients during cardiopulmonary bypass: a meta-analysis and semiquantitative review of randomized trials,” Journal of Cardiothoracic and Vascular Anesthesia, vol. 26, no. 3, pp. 448–454, 2012.

[87] A. J. Berson, J. M. Smith, S. E. Woods, K. A. Hasselfeld, and L. F. Hiratzka, “Off-pump versus on-pump coronary artery bypass surgery: does the pump influence outcome?” Journal of the American College of Surgeons, vol. 199, no. 1, pp. 102–108, 2004.

[88] G. D. Angelini, F. C. Taylor, B. C. Reeves, and R. Ascione, “Early and midterm outcome after off-pump and on-pump surgery in Beating Heart Against Cardioplegic Arrest Studies (BHACAS 1 and 2): a pooled analysis of two randomised controlled trials,” The Lancet, vol. 359, no. 9313, pp. 1194–1199, 2002.

[89] A. Syed, H. Fawzy, A. Farag, and A. Nemlander, “Comparison of pulmonary gas exchange in OPCAB versus conventional CABG,” Heart Lung and Circulation, vol. 13, no. 2, pp. 168–172, 2004.

[90] E. H. J. Hulzebos, P. J. M. Holders, N. J. Favié, R. A. de Bie, A. B. de La Riviere, and N. L. U. van Meeteren, “Preoperative intensive inspiratory muscle training to prevent postoperative pulmonary complications in high-risk patients undergoing CABG surgery: a randomized clinical trial,” Journal of the American Medical Association, vol. 296, no. 15, pp. 1851–1857, 2006.

[91] A. H. Herdy, P. L. B. Marochi, A. Vila et al., “Pre- and postoperative cardiopulmonary rehabilitation in hospitalized patients undergoing coronary artery bypass surgery a randomized controlled trial,” American Journal of Physical Medicine & Rehabilitation, vol. 87, no. 9, pp. 714–719, 2008.

[92] P. Agostini and S. Singh, “Incentive spirometry following thoracic surgery: what should we be doing?” Physiotherapy, vol. 95, no. 2, pp. 76–82, 2009.

[93] C. Urell, M. Emtner, H. Hedenström, A. Tenling, M. Breiden- skog, and E. Westerdahl, “Deep breathing exercises with positive expiratory pressure at a higher rate improve oxygenation in the early period after cardiac surgery—a randomised controlled trial,” European Journal of Cardio-Thoracic Surgery, vol. 40, no. 1, pp. 162–167, 2011.
[97] E. Westerdahl, B. Lindmark, T. Eriksson, Ö. Friberg, G. Hedenskrona, and A. Tenling, “Deep-breathing exercises reduce atelectasis and improve pulmonary function after coronary artery bypass surgery,” Chest, vol. 128, no. 5, pp. 3482–3488, 2005.

[98] C. R. F. Carvalho, D. M. Paisani, and A. C. Lunardi, “Incentive spirometry in major surgeries: a systematic review,” Revista Brasileira de Fisioterapia, vol. 15, no. 5, pp. 343–350, 2011.

[99] F. Guarracino, L. Cabrini, R. Baldassarri et al., “Non-invasive ventilation-aided transoesophageal echocardiography in high-risk patients: a pilot study,” European Journal of Echocardiography, vol. 11, no. 6, pp. 554–556, 2010.

[100] F. Guarracino, L. Cabrini, R. Baldassarri et al., “Noninvasive ventilation for awake percutaneous aortic valve implantation in high-risk respiratory patients: a case series,” Journal of Cardiothoracic and Vascular Anesthesia, vol. 25, no. 6, pp. 1109–1112, 2011.

[101] L. Cabrini, V. P. Plumari, L. Nobile et al., “Non-invasive ventilation in cardiac surgery: a concise review,” Heart, Lung and Vessels, vol. 5, pp. 137–141, 2013.

[102] L. Denehy and S. Berney, “The use of positive pressure devices by physiotherapists,” The European Respiratory Journal, vol. 17, no. 4, pp. 821–829, 2001.

[103] V. Squadrone, M. Coha, E. Cerutti et al., “Continuous positive airway pressure for treatment of postoperative hypoxemia: a randomized controlled trial,” Journal of the American Medical Association, vol. 293, no. 5, pp. 589–595, 2005.

[104] F. Pilkington, “Humidification for oxygen therapy in non-ventilated patients,” British Journal of Nursing, vol. 13, no. 2, pp. 111–115, 2004.

[105] C. Hormann, M. Baum, C. Putensen, N. J. Mutz, and H. Benzer, “Biphasic positive airway pressure (BiPAP)—a new mode of ventilatory support,” European Journal of Anaesthesiology, vol. 11, no. 1, pp. 37–42, 1994.

[106] S. Baudouin, S. Blumenthal, B. Cooper et al., “Non-invasive ventilation in acute respiratory failure: British thoracic society standards of care committee,” Thorax, vol. 57, no. 3, pp. 192–211, 2002.

[107] S. Stoltzfus, “The role of noninvasive ventilation: CPAP and BiPAP in the treatment of congestive heart failure,” Dimensions of Critical Care Nursing, vol. 25, no. 2, pp. 66–70, 2006.

[108] C. M. Roberts, J. L. Brown, A. K. Reinhardt et al., “Non-invasive ventilation in chronic obstructive pulmonary disease: management of acute type 2 respiratory failure,” Clinical Medicine, vol. 8, no. 5, pp. 517–521, 2008.

[109] C. R. Lopes, C. M. Brandão, E. Nozawa, and J. O. Auler Jr., “Benefits of non-invasive ventilation after extubation in the postoperative period of heart surgery,” Revista Brasileira de Cirurgia Cardiovascular, vol. 23, no. 3, pp. 344–350, 2008.

[110] M. García-Delgado, I. Navarrete, M. J. García-Palma, and M. Colmenero, “Postoperative respiratory failure after cardiac surgery: use of noninvasive ventilation,” Journal of Cardiothoracic and Vascular Anesthesia, vol. 26, no. 3, pp. 443–447, 2012.

[111] A. Kilic, N. Yapıcı, Y. Bicer, T. Corub, and Z. Aykac, “Early extubation and weaning with bilevel positive airway pressure ventilation after cardiac surgery (weaning with BiPAP ventilation after cardiac surgery),” Southern African Journal of Anaesthesia and Analgesia, vol. 14, no. 5, pp. 25–31, 2008.

[112] E. Al Jaaly, F. Fiorentino, B. C. Reeves et al., “Effect of adding postoperative noninvasive ventilation to usual care to prevent pulmonary complications in patients undergoing coronary artery bypass grafting: a randomized controlled trial,” The Journal of Thoracic and Cardiovascular Surgery, vol. 146, no. 4, pp. 912–918, 2013.

[113] P. Pasquina, P. Merlani, J. M. Granier, and B. Ricou, “Continuous positive airway pressure versus noninvasive pressure support ventilation to treat atelectasis after cardiac surgery,” Anesthesia and Analgesia, vol. 99, no. 4, pp. 1001–1008, 2004.